Bausch Health Companies (TSE:BHC) Raised to “Hold” at Jefferies Financial Group

Bausch Health Companies (TSE:BHC) was upgraded by research analysts at Jefferies Financial Group to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Bausch Health Companies Price Performance

TSE BHC opened at C$6.28 on Wednesday. Bausch Health Companies has a one year low of C$6.10 and a one year high of C$11.97. The stock has a 50-day moving average of C$7.04 and a 200 day moving average of C$7.69. The company has a debt-to-equity ratio of -1,009.96, a quick ratio of 0.58 and a current ratio of 1.32. The company has a market capitalization of C$2.35 billion, a price-to-earnings ratio of -1.94, a PEG ratio of 0.21 and a beta of 0.97.

Bausch Health Companies (TSE:BHC) last posted its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share (EPS) for the quarter. The business had revenue of C$3.51 billion for the quarter. Bausch Health Companies had a negative net margin of 13.54% and a positive return on equity of 120.43%. On average, sell-side analysts forecast that Bausch Health Companies will post 5.5472637 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.